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ABSTRACT:  
ATRX is a histone chaperone protein recurrently mutated in pediatric glioma. The 
mechanism which mediates the proliferative advantage of ATRX loss in pediatric glioma 
remains unexplained. Recent data revealed a distinct pattern of DNA binding sites of the ATRX 
protein using ChIP-seq in mouse neuronal precursor cells (mNPCs). Using the ATRX peaks 
identified in p53-/- mNPCs, we confirmed that ATRX binding sites were significantly enriched in 
gene promoters (p < 0.0001) and CpG islands (p < 0.0001) compared with random regions. Gene 
set enrichment (GSE) analysis identified that cell cycle and regulation of cell cycle were among 
the most significantly enriched gene sets (p=2.52e-16 and 1.61e-9, respectively). We found that 
ATRX loss resulted in dysfunction of G2/M checkpoint maintenance: (1) ATRX-deficient 
pediatric glioblastoma (GBM) cells exhibited a seven-fold increase in mitotic index at 16 hours 
after sub-lethal radiation, and (2) murine GBM cells with ATRX knockdown demonstrated 
impaired pChk1 signaling on western blot at multiple time points after radiation compared to 
controls (p=0.0187). Notably, the ATM signaling (pChk2) remained intact in those cells, 
suggesting a potential therapeutic target. ATRX-deficient mouse cells were uniquely sensitive to 
ATM inhibitors at 1 uM alongside 8 Gy radiation compared to controls with intact ATRX 
(AZD0156: p=0.0027 and AZD01390: p=0.0436). Mice intra-cranially implanted with ATRX-
deficient GBM cells showed improved survival (n=10, p=0.0018) when treated with AZD0156 
combined with radiation. Our findings suggest that ATRX loss in glioma results in unique 
sensitivity to ATM inhibition via epigenetic dysregulation of G2/M checkpoint maintenance. 
